Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 39% in the quarter

Alexion

3Q Revenues: $555.1 million (+39%)

3Q Earnings: $177.7 million (+89%)

YTD Revenues: $1.6 billion (+48%)

YTD Earnings: $503.6 million (+85%)

Comments: Soliris sales were $555.1 million in the quarter, up 39%, driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. R&D expenses were $100.7 million in the quarter, up 14%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters